Market Intelligence, ADME/Tox Profiling, and High-Purity Reagents for Drug-Drug Interaction (DDI) and Pharmacogenomic Screening.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CYP2C19 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYP2C19 Wild-Type & Mutant Proteins High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9/Insect cell expressed. |
View CYP2C19 Products |
| Gene Delivery | CYP2C19 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and metabolic assays. |
View CYP2C19 Products |
| Benchmark Ab | Anti-CYP2C19 Antibody Recombinant positive control for expression validation and Western Blotting. |
View CYP2C19 Products |
| Validator | CYP2C19 siRNA Set For knockdown verification in functional metabolic assays. |
View CYP2C19 Products |
| Related Target A | CYP3A4 Primary cytochrome P450 enzyme; critical for co-screening and comprehensive DDI profiling. |
View CYP3A4 Products |
| Related Target B | CYP2D6 Highly polymorphic metabolic enzyme; essential for cross-reactivity and selectivity panels. |
View CYP2D6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Microsomal Activity | High-purity recombinant CYP2C19 proteins co-expressed with NADPH-P450 Reductase (CPR) for optimal catalytic turnover. |
| Polymorphic Variant Screening (CYP2C19*2, *3, *17) | Sequence-verified recombinant mutant protein panels available for precision pharmacogenomics. |
| Lack of Controls | Clinical benchmark antibodies and chemical reference compounds included. |
| False Positives | Validated siRNA included for cell-based knockdown specificity checks. |
Live CYP2C19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for CYP2C19 therapeutics and profiling is intensifying, with small molecule developers shifting focus from generic ADME screening to high-throughput, early-stage drug-drug interaction (DDI) prediction. As next-generation therapies reach the clinic, the next wave of R&D is targeting precision pharmacogenomics, mapping how patient-specific CYP2C19 polymorphisms affect drug clearance and efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Global Pharma (Cardiovascular, CNS, Oncology) | Thrombosis (Clopidogrel), Depression, Acid-related disorders | In vitro metabolic clearance & DDI assays (Requires high-purity active CYP2C19 wild-type enzyme) |
| Companion Diagnostics (PGx) | Roche Diagnostics, Abbott, Qiagen | Personalized Medicine, Safety Screening | Genotyping assay validation (Requires sequence-verified CYP2C19*2, *3, *17 mutant panels) |